CSS
RPTX

Cubist Systematic Strategies’s Repare Therapeutics RPTX Stock Holding History

Cubist Systematic Strategies’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,175
Closed -$72.8K – 3489
2024
Q3 		$72.8K Buy
+21,175
New +$69.7K ﹤0.01% 2727
2024
Q2 		– Sell
-35,418
Closed -$167K – 3862
2024
Q1 		$167K Buy
35,418
+8,759
+33% +$56.1K ﹤0.01% 3145
2023
Q4 		$195K Buy
+26,659
New +$149K ﹤0.01% 3016
2023
Q1 		– Sell
-19,590
Closed -$288K – 4346
2022
Q4 		$288K Buy
+19,590
New +$293K ﹤0.01% 3385
2022
Q3 		– Sell
-106,053
Closed -$1.48M – 4681
2022
Q2 		$1.48M Buy
+106,053
New +$1.25M 0.01% 2136
2022
Q1 		– Sell
-29,943
Closed -$631K – 3741
2021
Q4 		$631K Buy
29,943
+29,843
+29,843% +$703K 0.01% 2278
2021
Q3 		$3K Buy
+100
New +$3.23K ﹤0.01% 2921
2021
Q2 		– Sell
-4,505
Closed -$138K – 3074
2021
Q1 		$138K Buy
4,505
+1,196
+36% +$40.6K ﹤0.01% 2582
2020
Q4 		$113K Buy
+3,309
New +$98.9K ﹤0.01% 2388

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cubist Systematic Strategies's RPTX Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Repare Therapeutics (RPTX) in Q4 2024, closing a stake of 21,175 shares — an estimated $72.8K sold.

Cubist Systematic Strategies first reported a position in RPTX in Q4 2020 and held it in 9 quarters. The position peaked at $1.48M in Q2 2022. 54 funds tracked by Wall St. Rank hold RPTX as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Repare Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 21,175 Repare Therapeutics shares in Q4 2024, an estimated $72.8K.
  • Cubist Systematic Strategies first reported a position in Repare Therapeutics in Q4 2020 and held it in 9 quarters.
  • Cubist Systematic Strategies's Repare Therapeutics position peaked at $1.48M in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.